The news ticker provides up-to-date press releases and company information for reading or downloading.

In COVID-19 times: Haupt Pharma Amareg produces disinfectant for the city of Regensburg

Haupt Pharma Amareg GmbH, member of the Aenova Group, has been supporting the city of Regensburg with disinfectants since the beginning of the corona crisis. Since March 2020, 12,000 litres have already been delivered.


COVID-19: Start of Phase 2 clinical trial of IMU-838

Immunic Therapeutics has received approval from German Health Authority (BfArM) to start a phase 2 clinical trial with its selective oral DHODH inhibitor IMU-838 for treatment of  COVID-19. We at the Aenova Group are grateful about the opportunity to participate in the development of the drug and supply of the material for the clinical study.


New Vice President Corporate HSES at Aenova Group

Dr Pedro Diaz Kraus is the new Vice President Corporate HSES at Aenova Group: „At Aenova we care for our customers and our employees in matters of Health and Safety as well as maintaining high Environmental and Sustainability standards for our products, processes and plants.”


New Head of Development Services at Aenova Group

Dr. Jörg Gampfer is the new head of development services at Aenova Group: „We offer a high level of quality and efficiency throughout all the stages of product development and manufacturing – that´s the Aenova approach.”


Angelo Gatto leaves Aenova Group

Angelo Gatto, Senior Vice President Global Sales & Marketing of the Aenova Group, is leaving the company at his own request.


CMO Leadership Awards: Aenova wins prizes in 3 categories

Renowed Life Science Leader´s CMO Leadership Award recognized the leading contract manufacturing organizations


COVID-19 Update March 2020

As we are navigating through an unprecedented global crisis, we would like to inform you what the Aenova Group is doing to manage through the COVID-19 pandemic.


Aenova Group successfully completes refinancing

The Aenova Group, one of the world’s largest Contract and Development Manufacturing Organisations (CDMO) to the pharmaceutical industry, announced today that it has successfully completed the refinancing of its capital structure.


Aenova Group appoints new CEO

The Supervisory Board of the Aenova Group, one of the world's leading providers of contract pharmaceutical manufacturing and development services, has appointed Jan Kengelbach as the company's new CEO.


Mohammad Naraghi leaves Aenova Group

Dr Mohammad Naraghi, CEO of Aenova Group, is leaving the company as of September 17. Jan Kengelbach will take on the tasks of CEO on an interim basis until a successor is found.


Aenova Group implements new manufacturing facility in Italy

The Aenova Group expands its Animal Health production with a new dedicated manufacturing area for solids veterinary pharmaceuticals in Latina (Italy). 


Aenova Group expands site in Cornu, Romania

The Aenova Group, one of the world's leading corporations in the pharmaceutical and healthcare industry, is significantly increasing its production capacity for soft gelatin capsules. The company is investing around 14 million euros into the expansion of its site in Cornu, Romania and will create almost 100 new jobs.


SPD-politician visits Aenova in Gronau

Federal Minister of Labour and Social Affairs, Andrea Nahles, received detailed information about high-quality pharmaceutical contract manufacturing „Made in Germany“ at the Aenova Group in Gronau (Lower Saxony). Together with the mayor of the municipality Gronau, Rainer Mertens, the minister visited the Lower Saxony site of Aenova, a worldwide leading company of the pharma- and healthcare-industry.


Aenova Group enlarges management team

The Supervisory Board of the Aenova Holding has appointed Mohammad Naraghi, M.D., Sc.D. (51) to the position of Chief Executive Officer (CEO) effective as of 15 May 2016. He will be responsible for Strategy, Marketing and Distribution as well as Research and Development, Communications, Quality and Human Resources. The Supervisory Board appointed Marco Robert Gorgas (45) as the new Chief Operating Officer (COO). From 1 June 2016, he will be in charge of Production and Supply Chain Management.


Marine Ingredients Acquires Softgel Production Facility

Aenova Group announced today that it has signed a definitive agreement to sell Swiss Caps USA’s softgel manufacturing facility in Miami, FL, to Marine Ingredients, a leading omega-3 manufacturer. As part of the agreement, the employees currently working in Miami will transfer from Swiss Caps USA to Innova Softgel, LLC, a newly formed subsidiary of Marine Ingredients. Both parties agreed not to disclose financial details of the transaction, which is expected to be closed by the end of December.


Aenova Group initiates restructuring of its management team

The Aenova Group, one of the world’s leading providers of contract manufacturing and development services to the pharmaceutical industry, has begun restructuring its management team.


Further acquisitions enhance the Aenova Group’s portfolio

The Aenova Group, one of the world’s largest pharmaceutical contract manufacturers, has successfully strengthened and developed its leading position on the European market by merging with Haupt Pharma at the beginning of the year. 
According to Heiner Hoppmann, the CEO of the Aenova Group, the organisation has now reached its necessary size and will focus primarily on qualitative growth over the next few years. 


Combining together on the road to success: Aenova and Haupt Pharma

The Aenova Group, one of the leading companies in the pharmaceutical and healthcare industry, is continuing its successful period of growth. As Aenova has already announced, it has found in Haupt Pharma, a company specializing in contract development and manufacturing for the pharmaceutical industry, a partner which will help it achieve a strategic expansion of its portfolio.


Aenova Group at the CPhI expo 2013

Aenova will be exhibiting at the CPhI Worldwide in Frankfurt from October 22 to 24, 2013. The CPhI (Convention on Pharmaceutical Ingredients) is the most important exhibition for the chemical and pharmaceutical processing industries and one of the largest pharmaceutical trade fairs in the world.


The Aenova Group's growth continues

With an increase in turnover of around three percent from € 262 million in 2011 to € 269 million in 2012, the Aenova Group further extended its market presence in 2012.


Successful integration

Successful integration as top managers from the Temmler Group join the Aenova management team in 2012.


Takeover of Euro Vital Pharma by the Aenova Group

The Aenova Group, one of the leading companies in the global pharmaceutical and healthcare industry, is taking over Euro Vital Pharma GmbH & Co. KG as part of its ongoing growth strategy.


Takeover of the Temmler Group by the Aenova Group

The Aenova Group, one of the leading companies in the global pharmaceutical and healthcare industry, is in the process of taking over the Temmler Group.


Aenova remains on track for expansion

The Aenova Group, one of the world’s leading companies in the pharmaceutical and healthcare industry, is presenting its extensive portfolio of services and its most recent innovations at CPhI in Madrid. Alongside Aenova’s comprehensive fullservice offering in the field of pharmaceutical development, the focus will also be on its enhanced expertise in multiple-unit pellet systems (MUPS) and the development and manufacturing of effervescent products at its Bad Aibling site.


Sabine Tedden is appointed HR director of Aenova

The Aenova Group has appointed Sabine Tedden as the new head of its HR department with immediate effect.